NUMERO: #20230867

Título: THE EFFECT OF THE SELECTIVE TRKB INHIBITOR IN A XENOGRAFT MODEL DERIVED FROM PATIENT WITH ORAL SQUAMOUS CELL CARCINOMA

Nome do Apresentador: Tuany Rafaeli SCHMIDT

Categoria do Trabalho: Painel de pesquisa científica (PPC)

Área Temática: Patologia Oral

Resumo: Objective: To evaluate the role of selective TrkB inhibitor (ANA-12) and cisplatin, alone or in combination, in oral squamous cell carcinoma (OSCC) patient-derived xenograft (PDX).
Study design: Three fresh OSCC fragments were collected from the surgical specimens of one patient undergoing surgery. Each tumor fragment was firstly grafted into a subcutaneous area on the back of 3 BALB/c nude mice for the OSCC-PDX - passage 0 (OSCC-PDX-0). OSCC-PDX-0 volumes were measured once a week and when it reached the endpoint volume of 1000 mm3 euthanasia was performed. The tumors were fragmented and implanted in 15 mice randomly divided into four groups: control (without treatment), cisplatin (weekly administration for 2 weeks), ANA-12 (daily administration for 15 days), and combined group (combined administration of the two therapies). The animals were evaluated for five weeks to assess the clinical effect.
Results: Cisplatin treatment promoted a decrease in tumor growth compared to the control group (0.002) and the combined group (0.016). ANA-12 and combined treatment had no impact on tumor growth.
Conclusion: ANA-12 isolate or combined to cisplatin were not efficient in the treatment of OSCC-PDX. In this sense, these therapies should not be considered as a promising therapy for targeting OSCC.

Autor 1:  Tuany Rafaeli SCHMIDT

E-mail 1:  [email protected]

Autor 2:   LAUREN FRENZEL SCHUCH

E-mail 2:  [email protected]

Autor 3 :  JOANA LETÍCIA SCHORR

E-mail 3:  [email protected]

Autor 4:  Fernanda Thomé Brochado

E-mail 4:  [email protected]

Autor 5:  Grazielle Oliveira Stelter

E-mail 5:  [email protected]

Autor 6:  Rafael Roesler

E-mail 6:  [email protected]

Autor 7:  MANOELA DOMINGUES MARTINS

E-mail 7:  [email protected]